DNA nanobots coming to your bloodstream

Bar Ilan University's Dr. Ido Bachelet is developing nanobots from DNA sequences for treating cancer.

Billions of robots built from DNA can live inside a syringe, and can be injected into the body, where they carry out search and destroy missions as they interact with the body and with each other. They locate tumors, release medications at the right place and in the right dosage, link up with each other to create a bridge on which tissue can grow, and with the press of an external button, they can disappear. This isn't science fiction, but applications of the nanobot technology developed by Dr. Ido Bachelet of Bar Ilan University.

Bachelet, a fresh acquisition from the Massachusetts Institute of Technology (MIT) under the reverse the brain drain program, says, "The pharmaceutical industry is constantly talking about better medicines, meaning medication which can be controlled. It's a bit like talking about a better gun, which only kills bad people. What would happen if we could give the rifle to a soldier who is trained to shoot exactly at the right time?"

Speaking at the TEDMED Israel conference, organized by Adv. Yaron Eliram and Dr. Eitam Eliram, in April, Bachelet held up a syringe, and said, "Here are 100 billion tiny robots, 50 nanometers in length. They were created in my joint work with Prof. Shawn Douglas, but at the Bar Ilan laboratory, we worked to make them more stable and safer."

How are nanometer robots produced? First, produce a DNA sequence of your choice, then replicate it using the origami DNA method. With this technique, a person can give orders to a computer to fold the DNA molecules as required. The result is, for example, a DNA sequence in the form of an oyster, whose pearl is medication, but the DNA includes a code that is activated when it comes into contact with particular materials in the body. For example, it is possible to ensure that the oyster receives a signal to change its shape and release the medication only when it encounters a tumor cell.

The molecules can also receive signals from each other. For example, it is possible to send two oysters, each of which has a different medication, both of which are essential, but are toxic when combined. Scientists can make sure that one oyster opens while the other stays closed.

"It is possible to ensure that there will be billions of molecules which react with each other. For example, it is possible to ask then to 'count', using chemicals, how many similar molecules are in their area, and then, when they reach a certain concentration, the oysters do not open. This protects the body from high concentrations of the drug," says Bachelet. He says that the processes of mutual signaling and counting give the accumulated robots the capabilities of a computer. "We create clusters of robots, which together operate the laws of logic at the level of an eight-kilobit computer, like the camcorder I had when I was a kid."

In theory, these robots can change their shape in response to signals from the body and link up with each other. When they reach the area of a wound, they can link up to become a bridge over the wound and excrete growth factors to encourage healing.

Another possibility is to send these robots through the body to seek tissues with particular characteristics, such as tumors.

Miniature antennas

This is not all. It is possible to include with the nanometer-sized DNA molecule a miniature antenna. When the antenna receives a signal, it causes a tiny change in the molecule, telling it to open or close, self-destruct, or attach to another molecule. The signal is sent from a transmitter outside the body, and the process is remotely controlled via the Internet.

Bachelet's nanobots can already carry out some of these interactions between each other, but what about interacting with the body? In the lab, Bachelet tests this on an unexpected lab animal - cockroaches.

"It is easy to work with them. You put them into the freezer for seven minutes, and they fall asleep. You inject the robots, thaw the cockroaches out, and they behave normally," says Bachelet. At this point, it is possible to see how and when the medication is excreted inside the cockroach, and it turns out that it is excreted where the researchers planned.

Published by Globes [online], Israel business news - www.globes-online.com - on May 27, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

Assaf Rappaport, Gil Shwed and Nadav Zafrir Can Check Point shake off its conservative ways?

The strategic partnership with Wiz is the first major decision by CEO Nadav Zafrir, after 30 years of Gil Shwed's cautious management.

Fintech Photo: Shutterstock Israeli fintech firm valuations plunge despite strong growth

"Globes" examines why Rapyd, Melio and eToro have halved their valuations, even though revenue and profitability are growing.

ERLOS plant in Germany credit: Peter Fenes EV battery recycling plant to open in Israel

Car importer Colmobil is leading the consortium building the plant based on German technology.

The man behind the hostage deal breakthrough

"Globes" profiles Steve Witkoff, the New York real estate businessman turned Middle East envoy.

Donald Trump  credit: Reuters/Brendan McDermid Trump tackles Gaza taboos

Donald Trump's White House press conference with Benjamin Netanyahu put an end to the assumption that he would have a restraining influence on Israeli policy.

Tel Aviv residential towers credit: Tamar Matsafi and Eyal Izhar Location, location, location. How true is it in Tel Aviv?

"Globes" examines prices in residential towers in the city to see whether the old real estate adage applies to Tel Aviv.

Blue agave fields in the Negev  credit: Alon Pearl Alcohol empire rising on Gaza border

Kibbutz Alumim is working on the first Israeli tequila, Kibbutz Beeri aims to establish a whiskey industry, while others dream of producing a world-class wine.

Tal Zaks credit: Dani Machlis Tal Zaks's Israeli startup targets rare genetic diseases

The former Moderna CMO, who led development of the company's Covid vaccine, tells "Globes" about Averna Therapeutics, which through gene editing is developing groundbreaking drugs.

Fazal Merchant credit: Sara Vaz "Within a year Wiz will be ready for an IPO"

In his first interview since being appointed CFO and president of Wiz, Fazal Merchant tells "Globes" about the Israeli cybersecurity company's future plans.

Aaron Frenkel credit: Eli Etkin Aaron Frenkel does it again

With a huge gain on the Bank Leumi stake he sold this week, the Israeli businessman again proved why he is the shrewdest investor on the TASE. "Globes" examines his remarkable track record and current investments.

Shahar Bar-Or credit: Eyal Izhar Infinidat Israel GM: Lenovo will help double our sales

Shahar Bar-Or tells "Globes" about the Herzliya-based enterprise storage startup's revival of fortunes, after it nearly went out of business in 2020, culminating in its $500 million acquisition by Lenovo.

Amit Krig  credit: Shlomi Yosef "People don't come to Nvidia just to earn a little more"

Nvidia SVP Amit Krig talks to "Globes" about the company's extraordinarily rapid expansion in Israel and its appeal to employees.

Itai Ben-Zaken  credit: Nir Hadar Applying Israeli tech to insuring US homes

Itai Ben-Zaken recovered from personal and business adversity to found Honeycomb, a fast-growing real estate insurance startup.

Displaced Palestinians in Khan Younis credit: Reuters Khalil Ramzi $80b to rebuild Gaza Strip - but who will rule?

The world is looking ahead to the enormous economic effort needed to rebuild Gaza. "Globes" asks who will pay such an amount and who will control the funds?

General (res.) Amos Yadlin  credit: Morag Bitan Amos Yadlin: The battle with Hamas isn't over

Former Military Intelligence chief Yadlin sees the deal with Hamas at this time as morally and strategically correct.

Amir Gal-Or credit: Koby Kantor OMGene.AI: Using DNA and AI to identify our strengths

Veteran Israeli venture capitalist Amir Gal-Or is launching an ambitious AI-enabled system that will produce personalized DNA-based recommendations.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018